Page last updated: 2024-10-30

mechlorethamine and Brill-Symmers Disease

mechlorethamine has been researched along with Brill-Symmers Disease in 11 studies

nitrogen mustard : Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR.

Research Excerpts

ExcerptRelevanceReference
"We reviewed all reported cases of Burkitt's lymphoma and/or Burkitt's leukemia (BLL) occurring following therapy for Hodgkin's disease."2.39Burkitt's lymphoma-leukemia in patients treated for Hodgkin's disease. ( Cooper, DL; Levy, A; Salloum, E; Tallini, G, 1996)
"The natural history of follicular lymphoma is believed not to have changed over the last 30 years."1.33New treatment options have changed the survival of patients with follicular lymphoma. ( Fisher, RI; LeBlanc, M; Maloney, DG; Miller, TP; Press, OW; Unger, JM, 2005)

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19906 (54.55)18.7374
1990's3 (27.27)18.2507
2000's2 (18.18)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Régis, A1
Ben Salem, D1
Lambert, A1
Couaillier, JF1
Casasnovas, O1
Piard, F1
Krausé, D1
MOLANDER, DW1
HALNAN, KE1
RABENKO, J1
CORREA URQUIZA, LM1
Fisher, RI2
LeBlanc, M1
Press, OW1
Maloney, DG1
Unger, JM1
Miller, TP1
Longo, DL1
Young, RC1
Hubbard, SM1
Wesley, M1
Jaffe, E1
Berard, C1
DeVita, VT1
Portlock, CS1
Jurcic, JG1
Koll, B1
Brown, AE1
Crown, JP1
Yahalom, J1
Gulati, SC1
Salloum, E1
Tallini, G1
Levy, A1
Cooper, DL1
Solal-Céligny, P1
Rywlin, AM1
Recher, L1
Hoffman, EP1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multicenter Phase II Study Evaluating BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Prior to Autologous Stem Cell Transplant for First and Second Chemosensitive Relapses in Patients With Follicular Lymphoma[NCT02008006]Phase 221 participants (Actual)Interventional2014-07-09Terminated (stopped due to Insufficient recruitment and unavailability of the treatment)
Ublituximab as Initial Therapy for Treatment-naive Follicular or Marginal Zone Lymphoma With Response-driven Addition of Umbralisib for Suboptimal Response[NCT04508647]Phase 24 participants (Actual)Interventional2020-11-23Completed
A Phase II Pilot Trial of CHOP Followed by Iodine-131-Labeled Monoclonal Anti-B1 Antibody for Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphomas[NCT00003784]Phase 2102 participants (Actual)Interventional1999-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Participants With Complete Response Rate (CR) at 8 Weeks Post Single Agent Induction

"Number of subjects that reached a complete response at the end of single agent induction as defined by a Lugano score of 3 or less on arm MONO - Monotherapy: Ublituximab.~Complete response assessed via PET CT scan utilizing the Lugano-Deauville Criteria where none of the lymphoma lesions had FDG ( FluoroDeoxyglucose) avidity greater than the liver uptake.~Patients who did not reach complete response at this point were then bridged to arm COMBO - Combotherapy: Ublituximab + Umbralisib." (NCT04508647)
Timeframe: 8 weeks post induction

InterventionParticipants (Count of Participants)
Ublituximab Only2

Number of Participants With Complete Response Rate (CR) at up to 12 Months Post MONO - Monotherapy: Ublituximab or Combotherapy: Ublituximab + Umbralisib.

"Number of subjects that reached a complete response at up to 12 months post induction as defined by a Lugano score of 3 or less on arms MONO - Monotherapy: Ublituximab.OR Combotherapy: Ublituximab + Umbralisib.~Complete response assessed via PET CT scan utilizing the Lugano-Deauville Criteria where none of the lymphoma lesions had FDG ( FluoroDeoxyglucose) avidity greater than the liver uptake." (NCT04508647)
Timeframe: up to 12 months post induction

InterventionParticipants (Count of Participants)
Ublituximab Only2
Ublituximab First, Then Ublituximab and Umbralisib2

Overall Response Rates (ORR) for Number of Participants

"Overall Response Rate for number of subjects as defined by a Lugano score of 3 or less on arms MONO - Monotherapy: Ublituximab.OR Combotherapy: Ublituximab + Umbralisib.~Overall response rate assessed via PET CT utilizing Lugano deauvile criteria where lymphoma lesions had responded and would include complete response, partial response (> 50% improvement) and stable disease (less than 50 % response)" (NCT04508647)
Timeframe: up to 12 months post induction

InterventionParticipants (Count of Participants)
Ublituximab Only2
Ublituximab First, Then Ublituximab and Umbralisib2

Reviews

2 reviews available for mechlorethamine and Brill-Symmers Disease

ArticleYear
Burkitt's lymphoma-leukemia in patients treated for Hodgkin's disease.
    Cancer investigation, 1996, Volume: 14, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Burkitt Lymphoma; Cyclophosphamide

1996
[Follicular lymphomas. Therapeutic indications].
    Presse medicale (Paris, France : 1983), 1992, Apr-11, Volume: 21, Issue:14

    Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub

1992

Other Studies

9 other studies available for mechlorethamine and Brill-Symmers Disease

ArticleYear
[Concomitant pulmonary Langerhans cell histiocytosis and malignant lymphoma: report of two cases].
    Journal de radiologie, 2009, Volume: 90, Issue:1 Pt 1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bleomycin; Combined Modality Therapy;

2009
THE MALIGNANT LYMPHOMAS.
    The American journal of nursing, 1963, Volume: 63

    Topics: Adrenal Cortex Hormones; Chlorambucil; Cyclophosphamide; Hodgkin Disease; Humans; Lymphoma; Lymphoma

1963
LONG-TERM RESULTS OF X-RAY TREATMENT IN MALIGNANT DISEASE OF THE LYMPHO-RETICULAR SYSTEM.
    Acta - Unio Internationalis Contra Cancrum, 1964, Volume: 20

    Topics: Classification; England; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Follicular; Lymphoma, Non-Hodg

1964
[The use of nitrogen mustard in the treatment of lymphatic diseases of a malignant type].
    Prensa medica argentina, 1959, Oct-09, Volume: 46

    Topics: Hodgkin Disease; Humans; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma,

1959
New treatment options have changed the survival of patients with follicular lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Nov-20, Volume: 23, Issue:33

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemothe

2005
New treatment options have changed the survival of patients with follicular lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Nov-20, Volume: 23, Issue:33

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemothe

2005
New treatment options have changed the survival of patients with follicular lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Nov-20, Volume: 23, Issue:33

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemothe

2005
New treatment options have changed the survival of patients with follicular lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Nov-20, Volume: 23, Issue:33

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemothe

2005
New treatment options have changed the survival of patients with follicular lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Nov-20, Volume: 23, Issue:33

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemothe

2005
New treatment options have changed the survival of patients with follicular lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Nov-20, Volume: 23, Issue:33

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemothe

2005
New treatment options have changed the survival of patients with follicular lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Nov-20, Volume: 23, Issue:33

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemothe

2005
New treatment options have changed the survival of patients with follicular lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Nov-20, Volume: 23, Issue:33

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemothe

2005
New treatment options have changed the survival of patients with follicular lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Nov-20, Volume: 23, Issue:33

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemothe

2005
Prolonged initial remission in patients with nodular mixed lymphoma.
    Annals of internal medicine, 1984, Volume: 100, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha

1984
Deferral of initial therapy for advanced indolent lymphomas.
    Cancer treatment reports, 1982, Volume: 66, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Therap

1982
Excretion of Ascaris lumbricoides during total body irradiation.
    Bone marrow transplantation, 1994, Volume: 13, Issue:4

    Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Ascariasis; Ascaris lumbricoides; Bo

1994
Lymphoma-like presentation of Kaposi's sarcoma. Three cases without characteristic skin lesions.
    Archives of dermatology, 1966, Volume: 93, Issue:5

    Topics: Aged; Blood; Blood Protein Electrophoresis; Diagnosis, Differential; Female; Hodgkin Disease; Humans

1966